Center for Cancer Nanotechnology Excellence
and Translation (CCNE-T)
Cedars-Sinai Medical Center Environment
Since being founded in 1902, Cedars-Sinai has been solely focused on providing the finest healthcare available. As a result, many advances in all areas of healthcare have been made and hundreds of thousands of lives have been significantly impacted. More than 1,800 physicians from virtually every medical specialty are affiliated with Cedars-Sinai. They join more than 8,000 employees, 2,000 volunteers and 15,000 fundraising support group members to form a unique partnership in delivering world-class medicine.
Cedars-Sinai physicians are leaders in basic and clinical research, bringing advancements in medicine directly from the laboratory to the bedside. In addition, they teach over 245 residents and fellows in nearly 60 graduate medical education programs at Cedars-Sinai.
Cedars-Sinai ranks as one of the top hospitals in clinical quality. Quality patient care and dedication to patient satisfaction are the cornerstones of Cedars-Sinai. Quality is measured in high patient satisfaction scores, continuous clinical performance activities, excellent medical outcomes, ongoing research and academic programs, and receipt of many designations and awards. Several different members of our CCNE-TR consortium are affiliated with Cedars-Sinai (Drs. Agus, Jain, and Mallick all part of Project 4).
The Cedars-Sinai Prostate Cancer Center (PCC) was built in 2000 and offers patients the best medical care possible and access to emerging therapies, through its research programs. Those programs include integrated prostate cancer clinical trials and a translational research lab that supports pre-clinical and clinical drug studies. In an ongoing effort to build one of the nation's leading research and prostate cancer treatment facilities, they have identified and recruited the best professionals in each related medical field to join our team. The Cedars-Sinai Prostate Cancer Center is an integral part of the UCLA Prostate SPORE (see support letter, Dr. Jean B. deKernion, PI UCLA Prostate SPORE) and one of the seven national Prostate Cancer Foundation Clinical Trial Consortium members. The recently established Spielberg Proteomics and High performance Computing Center of the PCC will house the outcomes projects described in this proposal.